Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure

被引:26
|
作者
Baker, DW
Bahler, RC
Finkelhor, RS
Lauer, MS
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA
[3] Metrohlth Med Ctr, Dept Med, Cleveland, OH USA
[4] Metrohlth Med Ctr, Div Cardiol, Cleveland, OH USA
[5] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0002-8703(03)00396-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The prevalence of left ventricular systolic dysfunction (LVSD) among individuals at risk for heart failure (HF) and the feasibility of screening have not been clearly defined. This study determined the prevalence of LVSD with the use of a limited screening echocardiogram among patients with risk factors for HF but no prior HF. Methods General medicine patients greater than or equal to60 years of age with hypertension, diabetes, coronary artery disease, or previous myocardial infarction (MI) but no history of HF or reduced left ventricular ejection fraction (LVEF) were eligible. Medical history and symptoms of breathlessness were determined by interview and chart review; consenting patients underwent electrocardiography and echocardiography. The outcome was LVEF less than or equal to45%, based on visual estimation from the echocardiogram. Results of the 482 patients who completed the study, only 1 patient could not have the LVEF visually estimated. A total of 7.9% of patients had LVEF less than or equal to45%. The prevalence was 15.4% among those with a prior MI and 6.7% among those without prior MI. In multivariate, analysis, prior MI (adjusted odds ratio, 2.75; 95% CI, 1.14 to 6.64) and probable or definite left ventricular hypertrophy by electrocardiography (adjusted odds ratio, 3.57; 95% Cl, 1.22 to 10.48) were the strongest predictors of LVEF less than or equal to 45%. Conclusions Screening for LVSD among high-risk patients is feasible and has substantial yield, even among patients without prior MI. In light of the low cost of screening and the available therapies to prevent progression of LVSD to overt HF, controlled clinical trials of screening high-risk subgroups appear to be justified.
引用
下载
收藏
页码:736 / 740
页数:5
相关论文
共 50 条
  • [21] PARADOXICAL INTRAVENTRICULAR SYSTOLIC FLOW PREDICTS HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
    Swiatkiewicz, Iwona
    Igata, Sachiyo
    Nishimura, Marin
    Strachan, Monet
    Raisinghani, Ajit
    DeMaria, Anthony
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1534 - 1534
  • [22] RACIAL DISPARITIES IN LEFT VENTRICULAR REMODELING AMONG PATIENTS WITH SYSTOLIC HEART FAILURE
    Dominguez, Yulanka Castro
    Jain, Shashank
    Mathur, Atish
    Raskin, Adam
    Wang, Frank
    Osorio, Carlos
    Patel, Monali
    Joseph, Vivek
    Solanki, Pallavi
    Klapholz, Marc
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1053 - A1053
  • [23] Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk
    Nielsen, OW
    Hilden, J
    Larsen, CT
    Hansen, JF
    HEART, 2001, 86 (02) : 172 - 178
  • [24] Diuretic Therapy in Elderly Heart Failure Patients With and Without Left Ventricular Systolic Dysfunction
    Dave J. W. van Kraaij
    René W. M. M. Jansen
    Frank W. J. Gribnau
    Willibrord H. L. Hoefnagels
    Drugs & Aging, 2000, 16 : 289 - 300
  • [25] Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study
    Davis, RC
    Hobbs, FDR
    Kenkre, JE
    Roalfe, AK
    Hare, R
    Lancashire, RJ
    Davies, MK
    BRITISH MEDICAL JOURNAL, 2002, 325 (7373): : 1156 - 1158A
  • [26] Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfunction
    van Kraaij, DJW
    Jansen, RWMM
    Gribnau, FWJ
    Hoefnagels, WHL
    DRUGS & AGING, 2000, 16 (04) : 289 - 300
  • [27] Mitral regurgitation and exercise capacity in heart failure patients with left ventricular systolic dysfunction
    Trivi, M.
    Thierer, J.
    Guglielmone, R.
    Adriana, A.
    Huschnir, P.
    Marino, J.
    Sultan, M.
    Mezzalira, V.
    Prado, A. Hirshon
    Ronderos, R.
    CIRCULATION, 2008, 118 (12) : E423 - E423
  • [28] Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction
    Mathew, J
    Lonn, E
    Johnstone, D
    Probstfield, J
    Arnold, M
    Baird, M
    Danisa, K
    Habib, N
    Bosch, J
    Pogue, J
    Yusuf, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 212A - 212A
  • [29] Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction?
    Aldo Pietro Maggioni
    Nature Clinical Practice Cardiovascular Medicine, 2005, 2 : 618 - 619
  • [30] Predicting left ventricular systolic dysfunction in patients with symptoms and signs of heart failure in the community
    Jeyaseelan, S
    Fahey, T
    Goudie, B
    Pringle, S
    Donnon, P
    Sullivan, F
    Struthers, A
    HEART, 2006, 92 : A41 - A41